Harrow, Inc. $HROW Shares Sold by Royce & Associates LP

Royce & Associates LP lowered its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 3.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 533,013 shares of the company’s stock after selling 20,680 shares during the quarter. Royce & Associates LP’s holdings in Harrow were worth $25,681,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. New York State Common Retirement Fund raised its holdings in shares of Harrow by 1,944.7% during the 3rd quarter. New York State Common Retirement Fund now owns 213,789 shares of the company’s stock worth $10,300,000 after acquiring an additional 203,333 shares during the period. Diametric Capital LP acquired a new stake in Harrow during the second quarter worth about $4,748,000. Bank of America Corp DE increased its position in Harrow by 266.8% during the second quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock worth $6,519,000 after purchasing an additional 155,258 shares during the last quarter. Divisadero Street Capital Management LP purchased a new position in Harrow during the second quarter worth about $4,293,000. Finally, Invesco Ltd. boosted its holdings in Harrow by 967.6% in the 2nd quarter. Invesco Ltd. now owns 150,948 shares of the company’s stock valued at $4,610,000 after purchasing an additional 136,809 shares during the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on HROW. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Harrow in a research report on Thursday, January 22nd. LADENBURG THALM/SH SH lifted their target price on Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. HC Wainwright boosted their price objective on shares of Harrow from $64.00 to $69.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $94.00 target price on shares of Harrow in a research note on Tuesday, November 11th. Finally, Zacks Research cut shares of Harrow from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 2nd. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $71.43.

Harrow Trading Up 0.4%

Shares of HROW stock opened at $54.18 on Monday. Harrow, Inc. has a fifty-two week low of $20.85 and a fifty-two week high of $54.85. The company has a 50 day moving average price of $48.53 and a 200 day moving average price of $43.70. The stock has a market capitalization of $2.01 billion, a P/E ratio of -541.75 and a beta of 0.05. The company has a debt-to-equity ratio of 5.21, a quick ratio of 2.52 and a current ratio of 2.72.

Harrow Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.